Search

everythinglearnresearchcommunity

for

Search:↓

PP405 is advancing to Phase 2b trials, showing promise from Phase 2a. It may be available in 3-6 years, with trials using a topical gel.

PP405 shows promise for hair regrowth by manipulating stem cell characteristics and lactate dehydrogenase, with Phase 2a trials pending. Google Ventures' $15M investment suggests confidence, but results and market availability remain uncertain.

PP405 is not a cure for hair loss but may reactivate dormant hair follicles, similar to minoxidil. It is unlikely to help with miniaturized or vellus hairs and is still in trial phases, with availability expected around 2030.

PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.

PP405 shows promise for hair follicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.

PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.

PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.

PP405 is a new hair growth stimulant different from Minoxidil, currently in phase 2 trials. Users discuss its potential, safety concerns, and the long wait before it might be available.

PP405, a topical LDH inhibitor, has shown to stimulate hair follicle stem cell proliferation in humans with moderate hair loss. They are advancing to more detailed trials this year.

The conversation is about the availability of the PP405 formula for hair loss treatment, with mentions of finasteride and its side effects. Users discuss the potential of obtaining the formula through unofficial channels and the challenges related to its genetic sequence and delivery method.

Skepticism about hair loss research motivations, suggesting financial interests hinder finding a cure. Mentions treatments like minoxidil, finasteride, and dutasteride, but notes they are not cures.

PP405 shows promise for reactivating hair follicles, with potential maintenance using 5AR inhibitors. Current treatments like Minoxidil and finasteride are effective but have limitations, and there is hope for more effective solutions in the future.

PP405 is a new topical treatment for hair loss, showing promise in trials but still requires finasteride for maintenance. There is skepticism about its effectiveness and safety, with concerns about needing finasteride to maintain results.

Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.

The conversation discusses updates on hair loss treatments, specifically GT20029, PP405, and a rumored injectable peptide from UT. GT20029 is seen as a promising treatment expected within 5-7 years.

The conversation discusses various hair loss treatments, including Breezula, KX826, and PP405, with mixed opinions on their effectiveness compared to finasteride and minoxidil. Some users express skepticism about the new treatments, while others remain hopeful about future developments.

Hair loss treatments like minoxidil, finasteride, TDM-105795, and PP405. MIT is hosting a hackathon to find innovative hair loss solutions.

New treatments for AGA are emerging, including pyrilutumide, gt0029, scube3, kx-826, and pp405. Verteporfin is mentioned as a promising option.

Finasteride, minoxidil, and derma rolling are currently the best treatments for hair loss. New treatments like TDM-105795, GT20029, PP405, HMI 115, Tsuji, Scube 3, RU, JW0061, Topilutamide, and verteporfin show promise but have uncertain timelines.

The conversation discusses various hair loss treatments, including pyrilutamide, RU58841, topical dutasteride, oral minoxidil, and oral finasteride/dutasteride. It also mentions potential treatments like PP405, Verteporfin, GT20029, and AMP303.

Stemson Therapeutics has shut down, disappointing those seeking a hair loss cure. Current treatments like minoxidil, finasteride, and dutasteride are discussed, with some users experiencing side effects and exploring alternatives like PP405.

The conversation discusses hair loss treatments, specifically Minoxidil, finasteride, and RU58841. One user questions if a treatment is a scam.

Hair loss treatments are advancing, with Coegin Pharma's FOL005 expected this year and Breezula potentially later. Pyrilutamide is available but not very effective, while Kintor's products face skepticism; traditional treatments like finasteride and minoxidil remain dominant.

Pyrilutamide is being discussed as a potential hair loss treatment, but opinions are mixed, with some users skeptical about its effectiveness and the company's credibility. Some users report combining pyrilutamide with other treatments like dutasteride and microneedling, noting improvements, while others remain doubtful.

Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.

Current hair loss treatments include finasteride, dutasteride, minoxidil, and derma rolling. New treatments like TDM-105795, GT20029, and others show promise but require more testing and time before approval.

Platelet-rich plasma (PRP) therapy for hair loss is expensive, painful, and often ineffective, with mixed reviews on its benefits. Alternatives like minoxidil, finasteride, and hair transplants are suggested as more reliable options.

JW0061 shows superior hair growth results compared to existing treatments, with significant increases in hair follicles. The Wnt/β-catenin pathway is crucial for hair growth, and JW0061 activates this pathway effectively.

Breezula, a potential new hair loss treatment, may receive FDA approval soon, but it is expected to be a weaker alternative to finasteride and minoxidil. Concerns include its twice-daily application and possible side effects like HPA axis suppression.

Bruce Willis's past comments on hair restoration and the progress of hair loss treatments like Minoxidil, Finasteride, and transplants. Users discuss the challenges of hair loss, the limited number of bald celebrities who are seen as role models, and the ongoing hope for future treatments.